A laboratory comparison of T cell depletion by CD34+ cell immunoaffinity selection and in vitro Campath-1M treatment: Clinical implications for bone marrow transplantation and donor leukocyte therapy

Bone Marrow Transplantation

Volumn 20, Issue 7, 1997, Pages 599-605

  Clarke, E ^a   Potter, M N ^b   Oakhill, A ^b   Cornish, J M ^b   Steward, C G ^b   Pamphilon, D H ^a,b  

^a NHS BLOOD AND TRANSPLANT   (United Kingdom)

^b BRISTOL ROYAL HOSPITAL FOR CHILDREN   (United Kingdom)

Author keywords

Bone marrow; Campath 1M; CD34+ cell enriched; Immunotherapy; Unadsorbed fraction

Indexed keywords

ALEMTUZUMAB; CD34 ANTIGEN;

ANTIBODY AFFINITY; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; BURST FORMING UNIT E; CLINICAL ARTICLE; COLONY FORMING UNIT GM; COMPARATIVE STUDY; CYTOLYSIS; HUMAN; HUMAN CELL; IMMUNOTHERAPY; LEUKOCYTE; LYMPHOCYTE SUBPOPULATION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0030667450     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1700937     Document Type: Article

References (32)

1. Oakhill A, Pamphilon DH, Potter MN et al. Unrelated donor bone marrow transplantation for children with relapsed acute lymphoblastic leukaemia in second complete remission. Br J Haematol 1996; 94: 574-578.
2. Arthur CK, Apperley JF, Guo D et al. Cytogenetic events after bone marrow transplantation for chronic myeloid leukemia in chronic phase. Blood 1988; 71: 1179-1186.
3. Cross NCP, Feng L, Chase A et al. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia after bone marrow transplantation. Blood 1993; 82: 1929-1936.
4. Steward CG, Goulden NJ, Katz F et al. A PCR study of the study of immunoglobulin heavy chain γ T cell receptors δ gene rearrangements between presentation and relapse of childhood B-lineage ALL. Blood 1994; 83: 1355-1362.
5. Kolb HJ, Mittermüller J, Clemm CH et al. Donor leukocyte transfusions for the treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462-2465.
6. Cullis JO, Jiang YZ, Schwarer AP et al. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood 1992; 79: 1379-1381.
7. Slavin S, Or R, Naparskek E et al. Cellular mediated immunotherapy of leukemia in conjunction with autologous and allogeneic bone marrow transplantation in animals and man. Blood 1988; 72: 407 (Abstr.).
8. Szer J, Grigg AP, Phillips GL, Sheridan WP. Donor leukocyte infusions after chemotherapy for patients relapsing with acute leukemia following allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 11: 109-111.
9. Slovak ML, Kopecky KJ, Wolman SR et al. Cytogenetic correlation with disease status and treatment outcome in advanced stage leukemia post-bone marrow transplantation: a Southwest Oncology Group Study (SWOG 8612). Leukemia Res 1995; 19: 381-388.
10. Ebell W, Reiter A, Riehm H. Chemotherapy vs bone marrow transplantation in childhood acute lymphoblastic leukaemia. BMF study group. Eur J Paediatr 1992; 151 (Suppl 1): S50-S54.
11. + cells from cord blood using dextran sedimentation and avidin column selection. Blood Cells 1994; 20: 397-403.
12. Berenson RJ, Bensinger WI, Kalamasz D. Positive selection of viable cell populations using avidin-biotin immunoadsorption. J Immunol Meth 1986; 91: 11-19.
13. Waldmann H, Polliak A, Hale G et al. Elimination of graft-versus-host disease by in vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984; 2: 483-486.
14. McNiece IK, Langley KE, Zsebo KM. Recombinant human stem cell factor synergises with GM-CSF, G-CSF, IL-3 and Epo to stimulate human progenitor cells of the myeloid and erythroid lineages. Exp Hematol 1991; 19: 226-231.
15. Sutherland HJ, Eaves CJ. Long-term culture of human myeloid cells. In: Frashney RI, Pragnell IB, Freshney MG (eds). Culture of Hematopoietic Cells. Wiley-Liss: New York, 1994, pp 139-151.
16. Sensebe L, Li J, Lilly M et al. Nontransformed colony-derived stromal cell lines from normal human marrows. 1. Growth requirement and myelopoiesis supportive ability. Exp Hematol 1995; 23: 507-513.
17. Kernan NA, Flomberg N, Collins N et al. Quantitation of T-lymphocytes in human bone marrow by a limiting dilution assay. Transplantation 1985; 40: 317-322.
18. + blood cells. Blood 1995; 86: 2500-2508.
19. Cullis JO, Szydlo RM, Cross N et al. Matched unrelated donor bone marrow transplantation for chronic myeloid leukaemia in chronic phase: comparison of ex vivo and in vivo T cell depletion. Bone Marrow Transplant 1993: 11 (Suppl 1): 107-111.
20. Apperley JF, Jones L, Hale G et al. Bone marrow transplantation for patients with Campath-1 reduces the incidence of graft-versus-host disease but may increase the risk of leukemic relapse. Bone Marrow Transplant 1986; 1: 53-66.
21. Hale G, Waldmann H, CAMPATH-1 monoclonal antibodies in bone marrow transplantation. J Hematother 1994; 3: 15-31.
22. + hematopoietic cells using an immunoaffinity column results in T cell depletion equivalent to elutriation. Exp Hematol 1995; 23: 320-322.
23. + blood cells. Blood 1996; 87: 4903-4909.
24. + peripheral blood stem cells in patients with advanced hematologic malignancy. Blood 1996; 88: 4132-4138.
25. + selection systems or Campath-1. Exp Hematol 1995; 23: 147-154.
26. Dickinson AM, Reid MM, Abinun M et al. In vitro T cell depletion using Campath-1M for mismatched BMT for severe combined immunodeficiency (SCID). Bone Marrow Transplant 1997; 19: 323-329.
27. Hale G, Bright S, Chumbley G et al. Removal of T cells from bone marrow for transplantation. A monoclonal anti-lymphocyte antibody that fixes human complement. Blood 1983; 62: 873-882.
28. Gilleece MH, Dexter TM. Effect of Campath-1H antibody on human hematopoietic progenitors in vitro. Blood 1993; 82: 807-812.
29. Slavin S, Naparstek E, Nagler A et al. Allogeneic cell therapy for relapsed leukaemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 1995; 23: 1553-1562.
30. Naparstek E, Or R, Nagler A et al. T-cell depleted allogeneic bone marrow transplantation for acute leukemia using Campath-1 antibodies and post transplant administration of donor peripheral blood lymphocytes for the prevention of relapse. Br J Haematol 1995; 89: 506-515.
31. Barrett AJ, Mavroudis D, Molldrem J et al. Optimizing the dose and timing of lymphocyte add-back in T-cell depleted BMT between HLA-identical siblings. Blood 1996; 88: 460 (Abstr.).
32. + depleted lymphocyte infusions as treatment for relapsed chronic myelogenous leukemia (CML) after allogeneic bone marrow transplantation (BMT): graft-versus-leukemia without graft-versus-host disease (GVHD). Blood 1994; 84: 538 (Abstr.).